» Articles » PMID: 37897549

Microglia Activation in Periplaque White Matter in Multiple Sclerosis Depends on Age and Lesion Type, but Does Not Correlate with Oligodendroglial Loss

Overview
Specialty Neurology
Date 2023 Oct 28
PMID 37897549
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple sclerosis (MS) is the most frequent inflammatory and demyelinating disease of the CNS. The disease course in MS is highly variable and driven by a combination of relapse-driven disease activity and relapse-independent disease progression. The formation of new focal demyelinating lesions is associated with clinical relapses; however, the pathological mechanisms driving disease progression are less well understood. Current concepts suggest that ongoing focal and diffuse inflammation within the CNS in combination with an age-associated failure of compensatory and repair mechanisms contribute to disease progression. The aim of our study was to characterize the diffuse microglia activation in periplaque white matter (PPWM) of MS patients, to identify factors modulating its extent and to determine its potential correlation with loss or preservation of oligodendrocytes. We analyzed microglial and oligodendroglial numbers in PPWM in a cohort of 96 tissue blocks from 32 MS patients containing 100 lesions as well as a control cohort (n = 37). Microglia activation in PPWM was dependent on patient age, proximity to lesion, lesion type, and to a lesser degree on sex. Oligodendrocyte numbers were decreased in PPWM; however, increased microglia densities did not correlate with lower oligodendroglial cell counts, indicating that diffuse microglia activation is not sufficient to drive oligodendroglial loss in PPWM. In summary, our findings support the notion of the close relationship between focal and diffuse inflammation in MS and that age is an important modulator of MS pathology.

Citing Articles

Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA).

Chisari C, Amato M, Di Sapio A, Foschi M, Iaffaldano P, Inglese M J Neurol. 2024; 271(10):6801-6810.

PMID: 39190108 PMC: 11446943. DOI: 10.1007/s00415-024-12621-9.


The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells.

Zveik O, Rechtman A, Ganz T, Vaknin-Dembinsky A Mol Neurodegener. 2024; 19(1):53.

PMID: 38997755 PMC: 11245841. DOI: 10.1186/s13024-024-00742-8.


Physiological aging and inflammation-induced cellular senescence may contribute to oligodendroglial dysfunction in MS.

Windener F, Grewing L, Thomas C, Dorion M, Otteken M, Kular L Acta Neuropathol. 2024; 147(1):82.

PMID: 38722375 PMC: 11082024. DOI: 10.1007/s00401-024-02733-x.

References
1.
Hendrickx D, van Scheppingen J, van der Poel M, Bossers K, Schuurman K, van Eden C . Gene Expression Profiling of Multiple Sclerosis Pathology Identifies Early Patterns of Demyelination Surrounding Chronic Active Lesions. Front Immunol. 2018; 8:1810. PMC: 5742619. DOI: 10.3389/fimmu.2017.01810. View

2.
Confavreux C, Vukusic S . Natural history of multiple sclerosis: a unifying concept. Brain. 2006; 129(Pt 3):606-16. DOI: 10.1093/brain/awl007. View

3.
Guneykaya D, Ivanov A, Perez Hernandez D, Haage V, Wojtas B, Meyer N . Transcriptional and Translational Differences of Microglia from Male and Female Brains. Cell Rep. 2018; 24(10):2773-2783.e6. DOI: 10.1016/j.celrep.2018.08.001. View

4.
Wendimu M, Hooks S . Microglia Phenotypes in Aging and Neurodegenerative Diseases. Cells. 2022; 11(13). PMC: 9266143. DOI: 10.3390/cells11132091. View

5.
Lublin F, Reingold S, Cohen J, Cutter G, Soelberg Sorensen P, Thompson A . Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014; 83(3):278-86. PMC: 4117366. DOI: 10.1212/WNL.0000000000000560. View